title: Genomic instability and poor prognosis associated with abnormal TP53 in breast carcinomas. Molecular and immunohistochemical analysis.
abstract: Alterations of the TP53 gene were analyzed in samples from 87 primary breast cancer patients, using molecular and immunohistochemical approaches. Mutations were detected in 17% of the samples, using polymerase chain reaction (PCR) and constant denaturant gel electrophoresis (CDGE) on exons 5-8 of the TP53 gene, and were confirmed by sequencing. Abnormal TP53 protein staining was found in 55% of the primary samples, using the monoclonal TP53 antibody DO7. A statistically significant association was found between TP53 mutations and abnormal protein staining (p = 0.002). Our results suggest that dysfunction of the TP53 protein is associated with tumor progression, as we found an association between TP53 abnormalities and accumulation of genetic lesions, measured as overall allelic imbalance (AI), homogeneously staining regions (HSR) and strong ERBB2 overexpression. Furthermore, patients with TP53 mutation had a highly elevated risk of dying from breast cancer during the study period (p < 0.001, RR = 10.68) at a median follow-up time of 42 months. Abnormal TP53 staining was much more frequent than the mutations, but it was not of prognostic significance, whereas strong staining was an independent prognostic factor. We therefore conclude that loss of functional TP53 leads to genetic instability, resulting in poorer short-term prognosis, and that only strong staining of TP53, and not abnormal protein staining in general, is of prognostic significance.
authors.affiliation: Molecular and Cell Biology Research Laboratory, Icelandic Cancer Society, Reykjavik, Iceland.
authors.forename: R
authors.initials: R
authors.lastname: Valgardsdottir
authors.forename: L
authors.initials: L
authors.lastname: Tryggvadottir
authors.forename: M
authors.initials: M
authors.lastname: Steinarsdottir
authors.forename: K
authors.initials: K
authors.lastname: Olafsdottir
authors.forename: S
authors.initials: S
authors.lastname: Jonasdottir
authors.forename: J G
authors.initials: JG
authors.lastname: Jonasson
authors.forename: H M
authors.initials: HM
authors.lastname: Ogmundsdottir
authors.forename: J E
authors.initials: JE
authors.lastname: Eyfjörd
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D001943:Breast Neoplasms / Q000737:chemistry / Q000235:genetics* / Q000401:mortality / Q000473:pathology*; D002277:Carcinoma / Q000737:chemistry / Q000235:genetics* / Q000401:mortality / Q000473:pathology*; D016158:Genes, p53; D006801:Humans; D007150:Immunohistochemistry; D008875:Middle Aged; D009154:Mutation; D011379:Prognosis; D018719:Erb-b2 Receptor Tyrosine Kinases / Q000096:biosynthesis / Q000235:genetics; D016159:Tumor Suppressor Protein p53 / Q000096:biosynthesis / Q000235:genetics
chemical_list: D018719:Erb-b2 Receptor Tyrosine Kinases; D016159:Tumor Suppressor Protein p53